Captario

Name: Captario
Brand: Captario

A major step-change in drug development: Captario SUM® provides advanced modeling, simulation, analytics, visualizations

Est 2012|Valuation $25.2M|Raised $15.7M|11 Ref Customers

LinkedIn 3K|Website|FTEs 20|HQ Gothenburg, Vastra Gotaland County, SE

MarketsScenario Modeling & "What-if" Analysis Strategic Portfolio Management (SPM)

01Competitive Landscape

| Aspect | Captario (Captario SUM) | Planisware (pharma PPM/SPM) | Sopheon Accolade | |--------|--------------------------|-----------------------------|-----------------| | Starting Price | Published pricing not available; vendor quote required | Published pricing not available; enterprise quotes typical | Published pricing varies by modules/users; confirm with vendor | | Best For | Pharma portfolio decision-making under uncertainty; simulation-driven scenario planning | Enterprise pharma project & portfolio management including execution governance | Innovation/strategic portfolio management with configurable workflows | | Key Strength | Probabilistic Monte Carlo portfolio simulation and interdependencies; vendor concept of an updating decision model | Broad PPM suite, governance, execution tracking; enterprise footprint | Structured portfolio process and innovation governance; cross-industry capabilities | | Key Weakness | Limited independent review evidence; public documentation on integrations and security beyond stated compliance claims is limited | Can be complex to implement; focuses on enterprise PPM capabilities rather than decision-science-first workflows | May require significant configuration/consulting; pricing and TCO can be substantial | - Direct competitors and their key differentiators - Captario: Emphasizes portfolio-scale probabilistic simulation with explicit interdependencies. - Planisware: Emphasizes broad enterprise PPM coverage including program/project governance, resource management, budgeting, and reporting for regulated industries. - Accolade: Emphasizes structured innovation portfolio governance and configurable workflows across industries. - Feature comparison: where this product excel vs lag behind - Likely excels - Portfolio uncertainty modeling and Monte Carlo at portfolio scale - Scenario exploration and propagation of input changes through portfolio outputs - Pharma-specific decision-science content and vendor positioning - Potentially lags (or at least is not proven publicly) - Breadth of classic PPM execution management (task-level delivery, time tracking) - Public ecosystem signals (marketplace listings, third-party reviews, community Q&A) - Pricing comparison: value proposition vs alternatives - Captario: published pricing not available; comparison requires vendor engagement and quotes. - Accolade: third-party sources discuss tiered subscription models; exact pricing depends on users/modules. - Planisware: typically enterprise quote-based pricing. - Customer testimonials comparing this product to competitors - No independent customer testimonials were found in the sources reviewed. - Market share and adoption trends - Vendor claims adoption by multiple enterprise pharma customers; independent market share data was not found in accessible sources. - When customers choose competitors instead (and why) - Common patterns (inferred; validate during vendor evaluation): - Choose Planisware/Sciforma when the primary need is broad PPM execution governance and enterprise reporting. - Choose Accolade when organization-wide innovation/stage-gate governance is the priority. - Choose SmartOrg when leadership seeks advisory-led decision analysis combined with tooling rather than a single SaaS platform.

01Competitive Landscape

Aspect	Captario (Captario SUM)	Planisware (pharma PPM/SPM)	Sopheon Accolade
Starting Price	Published pricing not available; vendor quote required	Published pricing not available; enterprise quotes typical	Published pricing varies by modules/users; confirm with vendor
Best For	Pharma portfolio decision-making under uncertainty; simulation-driven scenario planning	Enterprise pharma project & portfolio management including execution governance	Innovation/strategic portfolio management with configurable workflows
Key Strength	Probabilistic Monte Carlo portfolio simulation and interdependencies; vendor concept of an updating decision model	Broad PPM suite, governance, execution tracking; enterprise footprint	Structured portfolio process and innovation governance; cross-industry capabilities
Key Weakness	Limited independent review evidence; public documentation on integrations and security beyond stated compliance claims is limited	Can be complex to implement; focuses on enterprise PPM capabilities rather than decision-science-first workflows	May require significant configuration/consulting; pricing and TCO can be substantial

Direct competitors and their key differentiators
- Captario: Emphasizes portfolio-scale probabilistic simulation with explicit interdependencies.
- Planisware: Emphasizes broad enterprise PPM coverage including program/project governance, resource management, budgeting, and reporting for regulated industries.
- Accolade: Emphasizes structured innovation portfolio governance and configurable workflows across industries.
Feature comparison: where this product excel vs lag behind
- Likely excels
  - Portfolio uncertainty modeling and Monte Carlo at portfolio scale
  - Scenario exploration and propagation of input changes through portfolio outputs
  - Pharma-specific decision-science content and vendor positioning
- Potentially lags (or at least is not proven publicly)
  - Breadth of classic PPM execution management (task-level delivery, time tracking)
  - Public ecosystem signals (marketplace listings, third-party reviews, community Q&A)
Pricing comparison: value proposition vs alternatives
- Captario: published pricing not available; comparison requires vendor engagement and quotes.
- Accolade: third-party sources discuss tiered subscription models; exact pricing depends on users/modules.
- Planisware: typically enterprise quote-based pricing.
Customer testimonials comparing this product to competitors
- No independent customer testimonials were found in the sources reviewed.
Market share and adoption trends
- Vendor claims adoption by multiple enterprise pharma customers; independent market share data was not found in accessible sources.
When customers choose competitors instead (and why)
- Common patterns (inferred; validate during vendor evaluation):
  - Choose Planisware/Sciforma when the primary need is broad PPM execution governance and enterprise reporting.
  - Choose Accolade when organization-wide innovation/stage-gate governance is the priority.
  - Choose SmartOrg when leadership seeks advisory-led decision analysis combined with tooling rather than a single SaaS platform.

Aspect

Captario (Captario SUM)

Planisware (pharma PPM/SPM)

Sopheon Accolade

Starting Price

Published pricing not available; vendor quote required

Published pricing not available; enterprise quotes typical

Published pricing varies by modules/users; confirm with vendor

Best For

Pharma portfolio decision-making under uncertainty; simulation-driven scenario planning

Enterprise pharma project & portfolio management including execution governance

Innovation/strategic portfolio management with configurable workflows

Key Strength

Probabilistic Monte Carlo portfolio simulation and interdependencies; vendor concept of an updating decision model

Broad PPM suite, governance, execution tracking; enterprise footprint

Structured portfolio process and innovation governance; cross-industry capabilities

Key Weakness

Limited independent review evidence; public documentation on integrations and security beyond stated compliance claims is limited

Can be complex to implement; focuses on enterprise PPM capabilities rather than decision-science-first workflows

May require significant configuration/consulting; pricing and TCO can be substantial